Second chance: targeted radiation zaps recurrent prostate cancer
NCT ID NCT03246802
First seen Feb 02, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study tests a high-dose-rate brachytherapy (internal radiation) for men whose prostate cancer has returned after previous external beam radiation. About 30 participants will receive a targeted radiation implant to the area of recurrence, aiming to control the cancer while limiting side effects. The main goal is to track serious bowel or urinary side effects and quality of life over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BCCA Center for the Southern Interior
RECRUITINGKelowna, British Columbia, V1Y 5L3, Canada
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.